Clinical Trials Logo

Clinical Trial Summary

Microvascular angina (MVA) is caused by abnormalities of the small blood vessels in the heart. Endothelin-1 (ET-1) is a chemical messenger that circulates and accumulates in the blood vessel walls, causing them to narrow or go into spasm and thicken over a long period, especially as levels of ET-1 increase. As a result, patients experience pain, psychological distress and limitation of their daily activities. Cambridge is a participating recruitment site for a large randomised, double blinded, placebo controlled crossover trial (the PRIZE study: NCT04097314) investigating Zibotentan as a new drug treatment for patients with MVA using a 'precision medicine' approach. Zibotentan is a drug originally developed by Astra Zeneca for prostate cancer but prior research has shown that it acts to relax the small blood vessels of patients with MVA, highlighting its potential as a novel therapy for this patient group. The PRIZE study population will be enriched for 'responders' to the drug by screening patients with MVA for a gene mutation known to increase levels of circulating endothelin. The trial aims to initially invite approximately 356 participants for genetic testing but only 100 participants will go forward into the main study, with approximately 2/3rd being screen failures. In our sub-study, we will invite patients with MVA who are screen failures at our site for further blood tests looking for other genetic variants in the ET-1 signalling pathway and examine how this correlates with the severity of microvascular angina quantified by cardiac MRI and clinical assessments. Data from this sub-study would provide a bio-resource for further analysis of the main PRIZE trial to identify other patients that would benefit from Zibotentan.


Clinical Trial Description

Patients with microvascular angina (MVA) are under-diagnosed and have limited therapeutic options available to them. Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in the small vessel obstruction that causes MVA. The PRIZE trial will apply a precision medicine approach to assess the therapeutic effect of Zibotentan, an ET-1 antagonist (ETA) selective for the ETA receptor in patients who are high ET-1 expressors (possessing the PHACTR1 minor GG allele single nucleotide polymorphism - SNP). Unfortunately, the incidence of this SNP occurs in only a third of the population, resulting in a high screen-failure rate. In the proposed sub-study, we aim to recruit patients with MVA but without the minor GG allele SNP to potentially identify other potential 'responders' to Zibotentan. In an observational mechanistic study, we will perform baseline genotyping for other genetic variants in the ET-1 pathway as well as phenotyping patients by quantification of microvascular disease from retrospective analysis of cardiac MRI data. Patients will also complete angina and quality of life questionnaires and perform an exercise stress test to determine maximal exercise distance. Information from this sub-study will provide a genotype bio-resource that could identify novel SNPs for the pathogenesis of MVA that could be validated in the UK biobank. This may indicate other ETA receptor antagonist super-responders, justifying treatment with Zibotentan and enabling more patients with MVA to potentially benefit from this promising drug. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04508998
Study type Interventional
Source Papworth Hospital NHS Foundation Trust
Contact
Status Completed
Phase N/A
Start date May 14, 2021
Completion date August 13, 2022

See also
  Status Clinical Trial Phase
Completed NCT02147067 - Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA) Phase 2
Completed NCT06306066 - Coronary Thermo-dilution Derived Flow-indices in Chronic Coronary Syndrome
Recruiting NCT05288361 - The DISCOVER INOCA Prospective Multi-center Registry
Active, not recruiting NCT04777045 - Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial Phase 3
Completed NCT04097314 - Precision Medicine With Zibotentan in Microvascular Angina Phase 2
Recruiting NCT06025994 - Standardizing the Management of Patients With Coronary Microvascular Dysfunction N/A
Recruiting NCT04598308 - EUROpean Coronary microCirculatory Resistance and Absolute Flow Trial
Completed NCT03193294 - CORonary MICrovascular Angina (CorMicA) N/A
Not yet recruiting NCT02284048 - Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina Phase 4
Recruiting NCT00921856 - Abnormal Coronary Vasomotion in Patients With Suspected Coronary Artery Disease (CAD) N/A
Completed NCT02602600 - Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis Phase 4
Recruiting NCT06070662 - Non-invasive Diagnosis of Coronary Microvascular Disease: Pilot Study
Terminated NCT02914834 - Acupuncture for Individuals With Stable Angina N/A
Recruiting NCT05294887 - Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease Phase 4
Completed NCT02095964 - HDL-C in Cardiac Syndrome X N/A
Recruiting NCT06401291 - Transcutaneous Electrical Nerve Stimulation in Patients With Angina and Non-Obstructive Coronary Arteries N/A
Completed NCT04391491 - Neuregulin-1 in Patient With Different Forms of Cardiovascular Diseases: a Pilot Study
Recruiting NCT05635994 - Advanced Invasive Diagnosis for Patients With Chronic Coronary Syndromes Undergoing Coronary ANGIOgraphy (AID-ANGIO)
Recruiting NCT05313919 - Coronary Microcirculatory Disease and Inflammation in Patients With Chronic Coronary Syndrome and no Significant Coronary Artery Stenosis
Completed NCT05471739 - Simultaneous Assessment of Coronary Microvascular Dysfunction and Ischemia With Non-obstructed Coronary Arteries With Intracoronary Electrocardiogram and Intracoronary Doppler